Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.
- Activated Probiotics surpasses 1 million boxes sold
- Approaching number one probiotic in Australian pharmacies
- Fullscript Canada national launch expands North American presence
- BMB18 clinical trial and patent application underway
- Onshore manufacturing update expected in 2026
Activated Probiotics Surpasses Key Sales Milestone
Biome Australia Limited (ASX:BIO) has crossed a significant threshold, with its Activated Probiotics brand exceeding one million boxes sold on a rolling 12-month basis, a first for the company confirmed by independent pharmacy scan data. This milestone underscores the brand’s rapid ascent as the fastest-growing probiotic in Australian community pharmacies, driven by professional healthcare recommendations rather than seasonal buying patterns.
Since its launch in late 2019, Biome is on track to deliver its 100 millionth dose through community pharmacies and the healthcare practitioner channel within FY26, a scale of clinical impact achieved in under six years. The company’s flagship product, Biome Daily, is closing in on the number one probiotic product in Australian pharmacies by both units and value, reflecting strong consumer demand and practitioner trust.
Biome Daily Kids and Biome Baby are also leading growth in their respective segments, positioning the entire Activated Probiotics range in a rare growth trajectory among Australian probiotics. This momentum aligns with the company’s recent half-year results, which showcased a 40% revenue increase driven by clinical evidence and practitioner advocacy rather than marketing spend, as detailed in the company’s latest financial disclosures.
International Expansion Accelerates with Canadian Launch
Q3 FY26 saw Biome initiate a national launch of Activated Probiotics through Fullscript Canada, opening access to North America’s largest practitioner distribution channel. This move complements existing wholesale networks and marks a pivotal step in Biome’s international growth strategy, which also includes ongoing distribution in New Zealand, Ireland, and the UK. The Canadian launch is expected to diversify revenue streams and build on the company’s expanding global footprint.
Fullscript Canada serves over 100,000 healthcare practitioners and millions of patients, providing a powerful platform for Activated Probiotics to gain traction in a competitive market. This international push coincides with Biome’s largest-ever brand marketing investment, a national out-of-home and digital campaign running through major Australian metro markets to mid-May 2026, timed to capture heightened demand during the peak respiratory illness season.
BMB18 Clinical Trial and Intellectual Property Progress
Biome is advancing its innovation pipeline with the upcoming launch of the BMB18 human clinical trial at La Trobe University, scheduled for Q4 FY26. This randomised, double-blind, placebo-controlled study will enrol 240 participants to evaluate the proprietary probiotic strain discovered by Biome’s founder and science team. The trial aims to validate BMB18’s health benefits and support future product development.
In parallel, the company has lodged a patent application for BMB18, marking a critical milestone in its intellectual property strategy. The proprietary strain is expected to differentiate Activated Probiotics further in a crowded market, pending successful clinical outcomes and patent grant. This development follows Biome’s recent patent filing announcement and trial preparations, signalling a strategic focus on proprietary innovation.
Financial Position and Operational Efficiency
Biome reported a net increase in cash at bank to $3.387 million at the end of Q3 FY26, supported by positive operational metrics and secured financing facilities totaling $5 million with NAB. The company’s financial reporting is shifting to emphasise operational indicators, reflecting its evolution into a profitable, cash-generative enterprise. EBITDA for FY26 is expected to represent a transformational step-up compared to FY25, benefiting from operating leverage as the business scales.
The company clarified its expense reporting, highlighting that direct brand marketing investment accounts for only about 6.5% of sales, advertising, and marketing costs year-to-date, with the remainder comprising structural employee and distribution expenses. This breakdown reinforces that growth is predominantly driven by clinical credibility and practitioner advocacy rather than heavy marketing spend.
Onshore Manufacturing Update and Strategic Outlook
One of Biome’s most consequential near-term operational milestones is a substantive update on onshore Australian manufacturing, expected within calendar year 2026. This initiative aims to reduce cost of goods sold, mitigate supply chain and currency risks, and provide greater production agility to meet growing demand. Onshoring manufacturing aligns with the company’s Vision 27 strategy and could structurally improve margins as volumes increase.
Looking ahead to Q4 FY26, Biome is positioned to capitalise on an anticipated more severe respiratory illness season, its largest brand campaign, and the Canadian market launch. The company continues to expect profitability for FY26, contingent on normal trading conditions, as it leverages its strengthened brand and expanding distribution footprint.
Biome’s Managing Director Blair Vega Norfolk emphasised the resilience of the practitioner-led model through economic cycles and respiratory surges, attributing success to clinical evidence and practitioner trust rather than marketing alone. With innovation, international expansion, and operational improvements converging, Biome is setting the stage for its next phase of growth.
These developments build on Biome’s recent patent application for probiotic BMB18 and Fullscript Canada national launch, which have been key strategic milestones driving investor interest and market positioning.
Bottom Line?
Biome’s blend of clinical credibility, international expansion, and operational scaling positions it well for FY26 profitability, but upcoming clinical trial results and manufacturing updates will be pivotal to sustaining momentum.
Questions in the middle?
- Will the BMB18 clinical trial results validate Biome’s proprietary strain and support new product launches?
- How materially will onshore manufacturing reduce costs and improve supply chain resilience?
- Can Biome convert its international launches into significant revenue diversification beyond Australian pharmacies?